Bio-Gene Reports Strong Flavocide Results for Tick Control

Bio-Gene Technology Limited (ASX: BGT) announced that at the time of writing, new laboratory results from Purdue University have confirmed the efficacy of its novel insecticide Flavocide® in controlling ticks, a major vector of Lyme disease. The data were presented at the 17th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Chicago.

The studies showed that Flavocide achieved more than 90% mortality of Ixodes scapularis nymphs within 24 hours and demonstrated residual activity lasting up to four weeks under laboratory conditions. Conducted using a simulated tick habitat system, the results highlight Flavocide’s potential as a next-generation acaricide for both public and animal health applications. These findings, supported by the US Centers for Disease Control (CDC), reinforce Bio-Gene’s strategy of developing safer, nature-inspired solutions to tackle insecticide resistance and expand into global vector control markets.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com